WO2004105684A3 - Combination therapy for proliferative disorders - Google Patents

Combination therapy for proliferative disorders Download PDF

Info

Publication number
WO2004105684A3
WO2004105684A3 PCT/US2004/015346 US2004015346W WO2004105684A3 WO 2004105684 A3 WO2004105684 A3 WO 2004105684A3 US 2004015346 W US2004015346 W US 2004015346W WO 2004105684 A3 WO2004105684 A3 WO 2004105684A3
Authority
WO
WIPO (PCT)
Prior art keywords
type
involve administering
receptor agonist
methods involve
interferon receptor
Prior art date
Application number
PCT/US2004/015346
Other languages
French (fr)
Other versions
WO2004105684A2 (en
Inventor
Lawrence M Blatt
Scott D Seiwert
Osman N Ozes
Original Assignee
Intermune Inc
Lawrence M Blatt
Scott D Seiwert
Osman N Ozes
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Intermune Inc, Lawrence M Blatt, Scott D Seiwert, Osman N Ozes filed Critical Intermune Inc
Publication of WO2004105684A2 publication Critical patent/WO2004105684A2/en
Publication of WO2004105684A3 publication Critical patent/WO2004105684A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/212—IFN-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/217—IFN-gamma
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

The present invention provides methods of treating proliferative disorders, including angiogenesis-mediated disorders, cancer, and fibrotic disorders. In some embodiments, the methods involve administering a Type II interferon receptor agonist and a Type I interferon receptor agonist. In other embodiments, the methods involve administering a Type II interferon receptor agonist, a stress-activated protein kinase (SAPK) inhibitor, and a third therapeutic agent. In other embodiments, the methods involve administering a Type II interferon receptor agonist and a vascular endothelial growth factor (VEGF) antagonist. In other embodiments, the methods involve administering a VEGF antagonist and a SAPK inhibitor. The present invention further provides methods of treating fibrotic disorders. In some embodiments, the methods involve administering a Type I interferon receptor agonist, a Type II interferon receptor agonist; and a tumor necrosis factor (TNF) antagonist. In other embodiments, the methods involve administering a Type II interferon receptor agonist and a TNF antagonist. In other embodiments, the methods involve administering pirfenidone or a pirfenidone analog and a TNF antagonist. In other embodiments, the methods involve administering a Type II interferon receptor agonist and a transformining growth factor-beta (TGF-ß) antagonist. In other embodiments, the methods involve administering a SAPK inhibitor alone or in combination with a Type II interferon receptor agonist. In other embodiments, the methods involve administering N-acetyl cysteine (NAC) and a SAPK inhibitor. In other embodiments, the methods involve administering NAC and a Type II interferon receptor agonist.
PCT/US2004/015346 2003-05-16 2004-05-13 Combination therapy for proliferative disorders WO2004105684A2 (en)

Applications Claiming Priority (14)

Application Number Priority Date Filing Date Title
US47184103P 2003-05-16 2003-05-16
US60/471,841 2003-05-16
US48547403P 2003-07-08 2003-07-08
US60/485,474 2003-07-08
US51125903P 2003-10-14 2003-10-14
US51128003P 2003-10-14 2003-10-14
US51141503P 2003-10-14 2003-10-14
US60/511,280 2003-10-14
US60/511,259 2003-10-14
US60/511,415 2003-10-14
US51417303P 2003-10-24 2003-10-24
US60/514,173 2003-10-24
US56194004P 2004-04-13 2004-04-13
US60/561,940 2004-04-13

Publications (2)

Publication Number Publication Date
WO2004105684A2 WO2004105684A2 (en) 2004-12-09
WO2004105684A3 true WO2004105684A3 (en) 2008-12-11

Family

ID=33494402

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2004/015346 WO2004105684A2 (en) 2003-05-16 2004-05-13 Combination therapy for proliferative disorders

Country Status (1)

Country Link
WO (1) WO2004105684A2 (en)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT1928454E (en) * 2005-05-10 2014-12-04 Intermune Inc Pyridone derivatives for modulating stress-activated protein kinase system
AU2008265595B2 (en) 2007-06-20 2014-12-04 PureTech LYT 100 Inc. Substituted N-Aryl pyridinones as fibrotic inhibitors
JP5627574B2 (en) 2008-06-03 2014-11-19 インターミューン， インコーポレイテッド Compounds and methods for treating inflammatory and fibrotic diseases
US20110288134A1 (en) * 2008-10-29 2011-11-24 Pacific Therapeutics Ltd. Composition and method for treating fibrosis
US20110313004A1 (en) 2008-12-04 2011-12-22 Concert Pharmaceuticals, Inc. Deuterated pyridinones
WO2012122165A2 (en) 2011-03-08 2012-09-13 Auspex Pharmaceuticals, Inc. Substituted n-aryl pyridinones
AR092742A1 (en) 2012-10-02 2015-04-29 Intermune Inc ANTIFIBROTIC PYRIDINONES
US11446516B2 (en) 2013-08-09 2022-09-20 The Trustees Of The University Of Pennsylvania Methods of increasing response to cancer radiation therapy
EP3030268B1 (en) * 2013-08-09 2022-07-27 The Trustees Of The University Of Pennsylvania Combination of ifn-gamma with anti-erbb antibody for the treatment of cancers
CA2943363A1 (en) 2014-04-02 2015-10-08 Intermune, Inc. Anti-fibrotic pyridinones
GB201621728D0 (en) 2016-12-20 2017-02-01 Ucb Biopharma Sprl Methods

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0294160A1 (en) * 1987-06-02 1988-12-07 Schering Corporation Treatment of chronic type b hepatitis with a combination of recombinant human alpha and gamma interferons
US6040157A (en) * 1994-03-08 2000-03-21 Human Genome Sciences, Inc. Vascular endothelial growth factor 2

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0294160A1 (en) * 1987-06-02 1988-12-07 Schering Corporation Treatment of chronic type b hepatitis with a combination of recombinant human alpha and gamma interferons
US6040157A (en) * 1994-03-08 2000-03-21 Human Genome Sciences, Inc. Vascular endothelial growth factor 2

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
BERESINI ET AL.: "Overlapping Polypeptide induction in Human fibroblast in response to treatment with interferon alpha, gamma, interleukin 1 alpha, 1 beta and TGF" *
LUKACS ET AL.: "Type1/Type2 cytokine paradigm and the progression of Pulmonary Fibrosis", CHEST, vol. 120, 2001, pages 5 - 8 *

Also Published As

Publication number Publication date
WO2004105684A2 (en) 2004-12-09

Similar Documents

Publication Publication Date Title
WO2005107726A3 (en) Method for the treatment of back pain
WO2004105684A3 (en) Combination therapy for proliferative disorders
EP1944322A3 (en) Treatment of TNF alpha related disorders
WO2005079844A3 (en) Use for interleukin-33 (il33) and the il-33 receptor complex
NO20070514L (en) Pyrrolotriazine kinase inhibitors
WO2006047759A3 (en) Kinase inhibitors for the treatment of diabetes and obesity
MXPA05013642A (en) Composition of a vegf antagonist and an anti-proliferative agent and its use for the treatment of cancer.
WO2004089415A3 (en) COMBINATIONS OF AN 11β-HYDROXYSTEROID DEHYDROGENASE TYPE 1 INHIBITOR AND A GLUCOCORTICOID RECEPTOR AGONIST
WO2004110490A3 (en) Use of vegf inhibitors for tumor regression
EP2942082A3 (en) A2A receptor antogonists for use in the treatment of movement disorders
WO2010065751A3 (en) Formulations of guanylate cyclase c agonists and methods of use
WO2006018024A3 (en) Cosmetic and pharmaceutical compositions comprising ace inhibitors and/or angiotensin ii receptor antagonists
WO2006074265A3 (en) Drug combination therapy and pharmaceutical compositions for treating inflammatory disorders
JO2596B1 (en) Combinations comprising Epothilones and protein Tyrosine Kinase inhibitors and pharmaceutical uses thereof.
WO2005030187A3 (en) Iloprost in combination therapies for the treatment of pulmonary arterial hypertension
IL179206A0 (en) Pyrrolylpyrimidine derivatives and pharmaceutical compositions containing the same
WO2003015608A3 (en) Combination therapy for the treatment of cancer
WO2005024755A3 (en) Medicaments for the treatment of neurodegenerative disorders or diabetes
WO2002092016A3 (en) Therapeutic use of rank antagonists
WO2004009773A3 (en) Methods and compositions for activating or inhibiting vegf-d and vegf-c
WO2005115405A8 (en) Methods for treating or preventing restenosis and other vascular proliferative disorders
WO2004073649A3 (en) Clk-peptide and slk-peptide
WO2005058341A3 (en) Compositions for use in the treatment of mutant receptor tyrosine kinase driven cellular proliferative diseases
AU2002335027A1 (en) Treatment of tnf-alpha-mediated disorders with casein kinase i epsilon inhibitors
HK1079116A1 (en) Combined therapy against tumors comprising substituted acryloyl distamycin derivatives and radiotherapy

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase